Meropenem Enexi

Meropenem, the active ingredient in Meropenem Enexi, is a carbapenem antibiotic presented as an intravenous powder for reconstitution for use in severe bacterial infections. It is indicated for a range of serious infections in hospitalized patients, including intra‑abdominal, urinary, pulmonary, bloodstream and central nervous system infections. GNH USA supplies Meropenem Enexi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem Enexi is a broad‑spectrum carbapenem used to treat infections caused by susceptible bacteria in several organ systems.

Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure. Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens. Hospital‑acquired pneumonia: achieves high lung tissue concentrations for effective therapy. Septicemia: offers bactericidal activity against bloodstream infections. Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile colonisation - Rash or mild skin erythema - Headache - Elevated liver enzymes - Injection‑site phlebitis or discomfort

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment - Severe Clostridioides difficile‑associated colitis - Anaphylactic or anaphylactoid reactions - Acute renal failure or worsening renal function - Hematologic abnormalities such as neutropenia or thrombocytopenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Use meropenem with careful clinical assessment and monitoring.

Renal impairment: adjust dose based on creatinine clearance. Seizure risk: avoid in patients with a history of epilepsy or CNS disorders. Hypersensitivity: discontinue if allergic reactions develop. Antimicrobial stewardship: limit use to confirmed susceptible infections. Pregnancy and lactation: weigh benefits against potential risks; consult specialist. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - Oral contraceptives: may decrease hormonal efficacy, leading to unintended pregnancy. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined nephrotoxic potential requires renal function monitoring. - Aminoglycosides: additive renal toxicity; adjust dosing and monitor creatinine.